SCHEMBL4423151

SCHEMBL4423151

COc1ccc(-c2cccc3[nH]c4ncc(Cl)cc4c23)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KIT P10721 17/20 0.50
DYRK1A Q13627 1/20 0.46
NTRK1 P04629 1/20 0.44
MAP3K11 Q16584 1/20 0.43
AAK1 Q2M2I8 1/20 0.43
PIK3CA P42336 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4414511 0.79 MAPK14 (0.44) KITDYRK1ANTRK1
SCHEMBL3941571 0.76 AURKB (0.48)
SCHEMBL4423156 0.76 CHEK1 (0.44) DYRK1ANTRK1PIK3CA
SCHEMBL14293155 0.75 AXL (0.47) DYRK1A
SCHEMBL4421190 0.74 AURKA (0.44) NTRK1MAP3K11
SCHEMBL2122554 0.71 AURKA (0.45) KITNTRK1MAP3K11PIK3CA
SCHEMBL3949517 0.70 IMPDH2 (0.49)
SCHEMBL4415544 0.70 NQO2 (0.44) DYRK1A
SCHEMBL4421029 0.69 KIT (0.39) KITDYRK1A
SCHEMBL643897 0.68 AURKA (0.52) DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF XDH, F7, CYP4X1 KIT 705/4885DYRK1A 1718/4885NTRK1 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.